Takeda Pharmaceutical (TAK) Equity Ratio (2018 - 2026)

Takeda Pharmaceutical's Equity Ratio history runs 9 years deep, the most recent figure standing at 0.5 for Q1 2026.

• In Q1 2026, Equity Ratio rose 3.35% year-over-year to 0.5; the TTM figure through Mar 2026 stood at 0.5 (up 3.35% YoY), while the FY2026 annual figure was 0.5, up 3.35% from the prior year.
• Equity Ratio was 0.5 for Q1 2026 at Takeda Pharmaceutical, up from 0.5 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.5 in Q1 2026 to a low of 0.43 in Q1 2022.
• Historically, Equity Ratio has averaged 0.47 across 5 years, with a median of 0.48 in 2024.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio grew 8.93% in 2022, then rose 1.01% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.46 in 2022, then gained by 3.65% to 0.47 in 2023, then increased by 3.6% to 0.49 in 2024, then advanced by 1.01% to 0.5 in 2025, then increased by 1.42% to 0.5 in 2026.
• The last three Equity Ratio figures came in at 0.5 (Q1 2026), 0.5 (Q4 2025), and 0.49 (Q3 2025), per Business Quant data.